H
Holbrook E Kohrt
Researcher at Stanford University
Publications - 204
Citations - 15527
Holbrook E Kohrt is an academic researcher from Stanford University. The author has contributed to research in topics: Immunotherapy & Immune system. The author has an hindex of 54, co-authored 204 publications receiving 13179 citations. Previous affiliations of Holbrook E Kohrt include Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst,Jean-Charles Soria,Marcin Kowanetz,Gregg Fine,Omid Hamid,Michael S. Gordon,J. A. Sosman,David F. McDermott,John D. Powderly,Scott N. Gettinger,Holbrook E Kohrt,Leora Horn,Donald P. Lawrence,Sandra Rost,Maya Leabman,Yuanyuan Xiao,Ahmad Mokatrin,Hartmut Koeppen,Priti S. Hegde,Ira Mellman,Daniel S. Chen,F. Stephen Hodi +21 more
TL;DR: Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types.
Journal ArticleDOI
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,Ragini R. Kudchadkar,Natalie J. Miller,Lakshmanan Annamalai,Sneha Berry,Elliot Chartash,Adil Daud,Steven P. Fling,Philip Friedlander,Harriet M. Kluger,Holbrook E Kohrt,Lisa Lundgren,Kim Margolin,Alan Mitchell,Thomas Olencki,Drew M. Pardoll,Sunil Reddy,E. Shantha,William H. Sharfman,Elad Sharon,Lynn Shemanski,Michi M. Shinohara,Joel C. Sunshine,Janis M. Taube,John A. Thompson,John A. Thompson,Steven M. Townson,Jennifer H. Yearley,Suzanne L. Topalian,Martin A. Cheever,Martin A. Cheever +32 more
TL;DR: First-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56% and effectiveness was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing.
Journal ArticleDOI
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao,Ash A. Alizadeh,Chad Tang,June Helen Myklebust,June Helen Myklebust,Bindu Varghese,Saar Gill,Max Jan,Adriel C. Cha,Charles Chan,Brent T. Tan,Christopher Y. Park,Feifei Zhao,Holbrook E Kohrt,Raquel Malumbres,Javier Briones,Randy D. Gascoyne,Izidore S. Lossos,Ronald Levy,Irving L. Weissman,Ravindra Majeti +20 more
TL;DR: The eradication of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking anti-CD47 antibody, which synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers.
Journal ArticleDOI
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
TL;DR: The preclinical results suggest that the combination of PD-1/PD-L1 blockade and ibrutinib should be tested broadly in patients with lymphoma and also in other hematologic malignancies and solid tumors.
Journal ArticleDOI
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.
Alexander Filatenkov,Jeanette Baker,Antonia Ms Mueller,Justin A. Kenkel,G-One Ahn,Suparna Dutt,Nigel Zhang,Holbrook E Kohrt,Kent P. Jensen,Sussan Dejbakhsh-Jones,Judith A. Shizuru,Robert N. Negrin,Edgar G. Engleman,Samuel Strober +13 more
TL;DR: The results indicate that remissions induced by a short course of high-dose radiotherapy depend on the development of antitumor immunity that is reflected by the nature and kinetics of changes induced in the tumor cell microenvironment.